- Part 2: For the preceding part double click ID:nRSM6529Ja
occurred during the first
six months and their impact on the condensed set of financial statements, and
a description of the principal risks and uncertainties for the remaining six
months of the financial year; and
· Material related party transactions in the first six months and any
material change in related-party transactions described in the last annual
report.
By order of the Board
John Dawson
Chief Executive Officer
12 September 2016
Shareholder Information
DirectorsLorenzo Tallarigo(Non-executive Chairman) John Dawson(Chief Executive Officer) Tim Watts(Chief Financial Officer and Company Secretary) Peter Nolan(Chief Business Officer) Andrew Heath(Deputy Chairman and Senior Independent Director) Martin Diggle(Non-executive Director) Stuart Henderson(Non-executive director) Corporate BrokerJefferies Hoare GovettVintners Place68 Upper Thames StreetLondon EC4V 3B5 Financial AdviserWG Partners85 Gresham StreetLondon EC2V 7NQ RegistrarsCapita Asset ServicesThe Registry34 Beckenham RoadBeckenhamKent BR3 4TU Financial and Corporate
CommunicationsConsilium Strategic Communications41 LothburyLondon EC2R 7HG Registered AuditorsPricewaterhouseCoopers LLPOne Reading Central23 Forbury RoadReadingRG1 3JH SolicitorsCovington & Burling LLP265 StrandLondon WC2R 1BH
Registered Office Oxford BioMedica plcWindrush CourtTransport WayOxford OX4 6LTUnited Kingdom Tel: +44 (0) 1865 783 000Fax:+44 (0) 1865 783 001 enquiries@oxfordbiomedica.co.ukwww.oxfordbiomedica.co.uk
This information is provided by RNS
The company news service from the London Stock Exchange